Revance’s Phase II RT002 has three cervical dystonia patients still responding at 36 weeks; potential reduction in clinic visits major breakthrough – source

29 Jun 2017

Revance Therapeutics’ (NASDAQ:RVNC) RT002 (daxibotulinumtoxin a) is still demonstrating efficacy in three cervical dystonia patients after 36 weeks in an open-label Phase II trthat three ial, said a source familiar with the situation. The company recently presented positive 24-week efficacy/safety data and noted it would be measuring efficacy up to 36 weeks.

RT002 is designed to extend the length of efficacy of other toxin products, such as Allergan’s (NYSE:AGN) Botox (onabotulinum toxin A), noted the two sources. Other toxins have efficacy for 12-14 weeks and thus an improvement of 24 weeks is considered significant as it could half the number of clinician visits, they noted. However, the potential for patients to reduce the number of clinical visits even further would be a major clinical breakthrough, added the first source.

Analysts were positive regarding the 24-week data, noting it bodes well for future trials. RT002 could generate peak sales of up to USD 1.1bn, according to the same analyst report. Besides cervical dystonia, the drug is also being tested in glabellar lines and plantar fasciitis.

Already a subscriber? Login to read the full article.